Takeda Pharmaceutical Co Ltd (TKPHF) EBT Margin (2017 - 2026)
Takeda Pharmaceutical (TKPHF) posted quarterly EBT Margin of 13.34% for Q2 2026, down 27.0% year-over-year from 18.27% in Q2 2025, and little changed quarter-over-quarter from 13.34% in Q1 2026.
Takeda Pharmaceutical Co Ltd (TKPHF) EBT Margin (2017 - 2026) Analysis & Trends
Takeda Pharmaceutical's EBT Margin history runs 10 years deep, the most recent figure standing at 13.34% for Q2 2026.
- In Q2 2026, EBT Margin fell 27.0% year-over-year to 13.34%; the TTM figure through Jun 2026 stood at 2.63% (down 433.0% YoY), while the FY2026 annual figure was 3.16%, down 698.0% from the prior year.
- EBT Margin for Q2 2026 stood at 13.34%, roughly flat from 13.34% in the prior quarter.
- The five-year high for EBT Margin was 22.93% in Q1 2022, with the low at 41.57% in Q4 2025.
- The 5-year median for EBT Margin is 11.31% (2024), against an average of 7.66%.
- The sharpest annual moves came in 2022 and 2025: EBT Margin jumped 594 bps in 2022, then sank 3139 bps in 2025.
- Takeda Pharmaceutical's EBT Margin stood at 9.77% in 2022, then slumped by 53 bps to 4.56% in 2023, then sank by 323 bps to 10.19% in 2024, then slumped by 308 bps to 41.57% in 2025, then surged by 132 bps to 13.34% in 2026.
- Business Quant data shows TKPHF's EBT Margin at 13.34% in Q2 2026, 13.34% in Q1 2026, and 41.57% in Q4 2025.
Powered by 
Peer Comparison
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 13.34% |
| Mar 31, 2026 | 13.34% |
| Dec 31, 2025 | -41.57% |
| Sep 30, 2025 | 8.86% |
| Jun 30, 2025 | 13.61% |
| Mar 31, 2025 | 12.47% |
| Dec 31, 2024 | -10.19% |
| Sep 30, 2024 | 8.00% |
| Jun 30, 2024 | 11.31% |
| Mar 31, 2024 | 11.31% |
| Dec 31, 2023 | 4.56% |
| Sep 30, 2023 | 10.18% |
| Jun 30, 2023 | 12.76% |
| Mar 31, 2023 | 14.69% |
| Dec 31, 2022 | 9.77% |
| Sep 30, 2022 | 6.44% |
| Jun 30, 2022 | 15.99% |
| Mar 31, 2022 | 22.93% |
| Dec 31, 2021 | 8.01% |
| Sep 30, 2021 | 7.27% |